Medicinal cannabinoids are helpful for treatment of spasticity, pain, and bladder dysfunction for patients with multiple sclerosis (MS), although their efficacy is "limited," new research suggests.

The case series found consistent improvements in outcomes, demonstrating a unique use in management of MS symptoms AUSTIN, Texas, Aug. 24, 2023 /PRNewswire/ -- A case series conducted by Dr. Courtney ...

A study published in the Journal of Clinical Medicine indicated that vaporized cannabis containing standardized percentages of cannabidiol (CBD) and tetrahydrocannabinol (THC) produced sustained ...

LONDON, July 28 (Reuters) - GW Pharmaceuticals Plc's cannabis-derived medicine Sativex has been approved in its second European market, Spain, as an add-on therapy for treating spasticity in patients ...

WILMINGTON, N.C.--(BUSINESS WIRE)--Osmotica Pharmaceutical announced today that recruitment has begun for a Phase 3 clinical trial designed to assess the safety and efficacy of Arbaclofen Extended ...

There are no medications known to exacerbate MS disease processes, with the exception perhaps of the new anti-tumor necrosis factor (TNF) drugs used for inflammatory bowel disease and rheumatoid ...